

Date: 12/08/2021

Recommended Price: 310-318 • Target: 380-390 • Stoploss: 284

Time Frame: 6 months

Sharda Cropchem Ltd.



Technical Outlook

- On daily basis, the stock has taken trend line support and experienced a strong reversal. Furthermore, as shown in the above chart, the stock was able to maintain its 200 DSMA, which was acting as a strong support for the stock.
- Moreover, the stock on a daily scale has formed a bullish hammer candlestick pattern, indicating strength.
- The 200 DSMA is currently near 309 levels, and trend line support is near 300 levels, both of which were acting as strong supports for the stock.
- On a daily scale, the RSI is close to the oversold zone, and the stochastic oscillator has seen a bullish crossover from an oversold zone. As a result, a bounce from the oversold zone is possible.
- Based on the above technical setup, we recommend buying SHARDACROP in the range of 310-318 with a stop loss of 284 on a closing basis for a medium-term target of 380-390.

Fundamental Rationale

- Sharda Cropchem is principally engaged in export of agrochemicals (such as technical grade and formulations) and non-agro products such as conveyor belts, rubber belts/sheets, dyes and dye intermediates to various countries across the world.
- It follows a unique asset-light business model in which it totally outsources agrochemical manufacturing to China and concentrates on product registrations. Once these opportunities are identified, it immediately begins the process of seeking registration from regional authorities.
- The company derived 86% of revenue from agrochemicals segment and 14% from the non-agrochem business in FY21. The company has a portfolio of 2,543 product registrations and a pipeline of 1,128 registrations across the regions as of Mar-2021. It procures 100 - 150 registrations every year and the company has its presence with a marketing network across 80 countries.
- The Non Agro Business witnessed the real impact of COVID-19. All the material handling at ports, mines, etc. has been impacted adversely. Now, as these activities are normalising and demand is improving, the non-agrochem business should grow, in our view.
- In FY22, the company anticipates revenue growth of 10-15% and a margin of 18-19%. In the next three to four years, it wants to surpass Rs 3,000 crore in revenue (FY21: Rs.2,396Crore). We believe the company is likely to maintain growth momentum due to rising wallet share in existing products, new launches, and the expansion of the in-house sales team.

ACMIIL Retail Research Products

Informational Products	Recommendation Products
Morning Notes	Momentum Calls
Market Watch	Positional Calls
Investor First Magazine	Smart Delivery Calls
IPO/NCD/ETF/OFS/BOND	Investment Ideas
Market Pulse	Master Trades High Risk
RBI Monetary Policy	Master Trades Medium Risk
Union Budget Report	Techno-Funda
Weekly Derivative Synopsis	Top Mutual Fund Schemes
Rollover Snapshot	Portfolio Review
Rollover Analysis	Stock Basket

For More Information on Retail Research Products please visit
<https://www.investmentz.com/research-services>

Asit C. Mehta

INVESTMENT INTERMEDIATES LTD.

Email: retailresearch@acm.co.in

Research Analyst Registration Number:
INH000002483

CIN: U65990MH1993PLC075388

An ISO 9001:2015 Certified Company

Download Investmentz App



Follow us on:



Information pertaining to Asit C. Mehta Investment Intermmediates Limited (ACMIIL):

ACMIIL is a SEBI registered Stock Broker, Merchant Banker, Portfolio Manager and Depository Participant. It is also a AMFI registered Mutual Fund Distributor. It does not have any disciplinary history. Its associate/ group companies are Asit C. Mehta Commodity Services Limited, Asit C. Mehta Realty Services Pvt. Ltd, Asit C. Mehta Forex Pvt. Ltd, Nucleus IT Enabled Services , Asit C. Mehta Financial Services Limited (all providing services other than stock broking,merchant banking and portfolio management services.).

Disclosures

ACMIIL/its associates and its Research analysts have no financial interest in the companies covered on the report. ACMIIL/its associates and Research analysts did not have actual/beneficial ownership of one per cent or more in the companies being covered at the end of month immediately preceding the date of publication of the research report. ACMIIL/its associates or Research analysts have no material conflict of interest, have not received any compensation/benefits for any reason (including investment banking/ merchant banking or brokerage services) from either the companies concerned/third parties with respect to the companies covered in the past 12 months. ACMIIL/its associates and research analysts have neither managed or co-managed any public offering of securities of the companies covered nor engaged in market making activity for the companies being covered. Further, the companies covered neither are/nor were a client during the 12 months preceding the date of the research report. Further, the Research analyst/s covering the companies covered herein have not served as an officer/director or employee of the companies being covered

Disclaimer:

This report is based on information that we consider reliable, but we do not represent that it is accurate or complete and it should not be relied upon such. ACMIIL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in the report. To enhance transparency we have incorporated a Disclosure of Interest Statement in this document. This should however not be treated as endorsement of the views expressed in the report.

You are also requested to refer to the disclaimer (which is deemed to be part and parcel and is applicable to this research report as well) : <http://www.investmentz.com/disclaimer>